Skip to main content
. 2022 Jul 25;13:955158. doi: 10.3389/fneur.2022.955158

Table 3.

Efficacy of botulinum toxin type A injection.

Parameters Baseline After treatment p -value a
Headache profile
Frequency (days/month) 17.8 ± 9.9 9.5 ± 10.1 0.001
Severity (VAS, 1–10) 6.8 ± 1.3 5.0 ± 2.6 <0.001
HIT-6 (6 questions, 78 points) 65.0 ± 7.4 55.2 ± 8.8 <0.001
Severe headache (HIT-6 ≥ 60 points) 17 (85%) 7 (35%) 0.002b
MIDAS (5 questions, days/3 month) 53.3 ± 29.4 28.3 ± 30.3 0.001
grade 1 (MIDAS score 0–5) 0 (0%) 8 (40%) 0.002b
grade 2 (MIDAS score 6–10) 0 (0%) 2 (10%)
grade 3 (MIDAS score 11–20) 3 (15%) 0 (0%)
grade 4 (MIDAS score ≥21) 17 (85%) 10 (50%)
MSQ (14 questions, 100 points) 68.8 ± 47.1 105.0 ± 40.3 <0.001
MSQ_RR (7 questions) 23.9 ± 15.0 36.1 ± 13.7 0.001
MSQ_RP (4 questions) 24.3 ± 15.8 34.5 ± 14.4 0.003
MSQ_EF (3 questions) 20.7 ± 18.1 34.3 ± 16.8 0.001
Vestibular symptom profiles
Frequency (days/month) 14.0 ± 5.0 8.5 ± 5.4 <0.001
Intensity (VAS-D, 0–10) 6.0 ± 2.8 3.7 ± 2.7 0.001
VSS (15 questions, 60 points) 30.1 ± 10.5 18.2 ± 11.3 <0.001
DHI (25 questions, 100 points) 52.4 ± 27.8 31.6 ± 22.9 <0.001
Physical (7 questions, 28 points) 11.6 ± 6.6 7.9 ± 5.2 0.001
Functional (9 questions, 36 points) 20.1 ± 11.9 13.8 ± 10.5 0.015
Emotional (9 questions, 36 points) 19.2 ± 10.0 10.1 ± 9.0 <0.001
Depression and anxiety profile
BDI (21 questions, 63 points) 23.9 ± 15.6 16.0 ± 11.0 <0.001
BAI (21 questions, 63 points) 26.6 ± 14.7 16.7 ± 13.0 0.001

VAS, visual analog scale; HIT-6, Headache Impact Test-6; MIDAS, Migraine Disability Assessment; MSQ, Migraine Specific Quality of Life; RR, Role-function Restrictive; RP, Role-function Preventive; EF, Emotional Function; VAS-D, Visual Analog Scale-Dizziness; VSS, Vertigo Symptom Scale-short form; DHI, Dizziness Handicap Inventory; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.

a

Paired t-test;

b

Pearson's chi-square test.